Compare AIRE & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AIRE | KPRX |
|---|---|---|
| Founded | 2021 | 1998 |
| Country | United States | United States |
| Employees | N/A | 13 |
| Industry | | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.5M | 11.7M |
| IPO Year | 2023 | N/A |
| Metric | AIRE | KPRX |
|---|---|---|
| Price | $1.48 | $2.54 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $1.30 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 44.0K | 19.6K |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.34 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,518,498.00 | N/A |
| Revenue This Year | $129.06 | N/A |
| Revenue Next Year | $83.72 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 376.42 | N/A |
| 52 Week Low | $0.16 | $1.76 |
| 52 Week High | $3.98 | $3.23 |
| Indicator | AIRE | KPRX |
|---|---|---|
| Relative Strength Index (RSI) | 30.96 | 56.29 |
| Support Level | $0.29 | $2.44 |
| Resistance Level | $2.17 | $2.72 |
| Average True Range (ATR) | 0.16 | 0.09 |
| MACD | -0.06 | 0.00 |
| Stochastic Oscillator | 0.00 | 64.52 |
ReAlpha Tech Corp is a real estate technology company. The group is engaged in an end-to-end commission-free homebuying platform. It develops and utilizes its artificial intelligence-focused technology stack to empower retail investor participation in short-term rental properties, which are real estate units listed for a rental term. It provides short-term rental investment opportunities to everyday investors. The company has developed technologies and tools that allow for the analysis of short-term rental properties using AI to provide insight into that property's potential profitability and ways to increase such profitability. The company's reportable segments are Homebuying Services and the Technology Services segment.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.